Alemtuzumab: all 222 studies that test it
Page 2 of 3. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid DisordersCompletedNCT00071396Phase 2Results posted
- Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell LymphomasCompletedNCT00069238Phase 2Results posted
- Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic AnemiaCompletedNCT00065260Phase 2Results posted
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic LeukemiaCompletedNCT00061945Phase 1/2Results posted
- Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital AnemiasActive, not recruitingNCT00061568Phase 1/2Results posted
- Campath-1H for Treating Adult T-Cell Leukemia/LymphomaCompletedNCT00061048Phase 2Results posted
- Stem Cell Transplant for Hematologic DiseasesTerminatedNCT00058825Phase 1/2Results posted
- A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple SclerosisCompletedNCT00050778Phase 2Results posted
- Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary SyndromeCompletedNCT00047060Phase 1/2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
- Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
- Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure SyndromesCompletedNCT00004143Phase 2Results posted
- TMLI and Alemtuzumab for Treatment of Sickle Cell DiseaseActive, not recruitingNCT05384756Phase 1
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-ThalassemiaActive, not recruitingNCT05357482Phase 1/2
- Reduced Intensity Transplantation for Severe Sickle Cell DiseaseActive, not recruitingNCT04362293Phase 2
- Autologous Transplant Targeted Against Crohn'sWithdrawnNCT04154735Phase 2
- Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04018937Phase 2
- Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic LeukemiaCompletedNCT03989466Phase 1
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant CyclophosphamideActive, not recruitingNCT03910452Early Phase 1
- Tolerance by Engaging Antigen During Cellular HomeostasisCompletedNCT03504241Phase 1
- Stem Cell Transplant in Patients With Severe Sickle Cell DiseaseTerminatedNCT03421756Early Phase 1
- Precision Dosing of AlemtuzumabCompletedNCT03302754Not applicable
- Cyclophosphamide and Alemtuzumab In LymphomaTerminatedNCT03132584Phase 1
- Cyclosporine Plus Methotrexate or AlemtuzumabTerminatedNCT02701517Phase 2
- Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell DiseaseTerminatedNCT02678143Phase 1
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid TumorsTerminatedNCT02653196Early Phase 1
- High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous DiseaseActive, not recruitingNCT02629120Phase 1/2
- Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)Status unknownNCT02529839Not applicable
- Treatment of Familiar LymphohistiocytosisCompletedNCT02472054Phase 1/2
- Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective PotentialCompletedNCT02419378Phase 4
- Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADACompletedNCT02205489Phase 4
- Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic LeukemiaSuspendedNCT01982175Phase 2
- CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell LymphomaCompletedNCT01806337Phase 2
- Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)WithdrawnNCT01757574Phase 4
- High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior TreatmentTerminatedNCT01679041Phase 2
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis CongenitaActive, not recruitingNCT01659606Phase 2
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesActive, not recruitingNCT01652092Not applicable
- Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced SubjectsStatus unknownNCT01624714Phase 1
- Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)Active, not recruitingNCT01499888Phase 1/2
- Alemtuzumab for ANCA Associated Refractory VasculitisStatus unknownNCT01405807Phase 4
- Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to FludarabineCompletedNCT01392079Phase 2
- Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis PatientsStatus unknownNCT01333358Phase 3
- Advanced MRI Measures of Repair in Alemtuzumab Treated PatientsCompletedNCT01307332Phase 3
- Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)CompletedNCT01186640Phase 2
- Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT00951457Phase 1/2
- Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00947388Phase 1
- Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic MalignanciesTerminatedNCT00943293Phase 1
- The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)CompletedNCT00930605Phase 2
- A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00923182Phase 1
- Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin LymphomaStatus unknownNCT00908180Phase 2
- Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin LymphomaStatus unknownNCT00907036Phase 2
- Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow FailureStatus unknownNCT00895739Phase 2
- Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)TerminatedNCT00881556Early Phase 1
- Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After ChemotherapyStatus unknownNCT00800943Phase 2
- Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity ConditioningTerminatedNCT00781781Phase 2
- Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell TransplantsCompletedNCT00775632Phase 2
- Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic LeukemiaCompletedNCT00773149Phase 1/2
- Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune CytopeniasCompletedNCT00749112Phase 2/3
- Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOPStatus unknownNCT00725231Phase 3
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal TransplantationCompletedNCT00685061Phase 4
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal TransplantationCompletedNCT00681343Phase 4
- A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.TerminatedNCT00637390Phase 1
- Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00634881Phase 1/2
- Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal TransplanationTerminatedNCT00579592Not applicable
- A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of ResponseCompletedNCT00565981Phase 2
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell LymphomaStatus unknownNCT00562068Phase 1
- Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic DisordersCompletedNCT00533923Phase 2
- The Efficacy and Safety of Alemtuzumab in Auotoimmune CytopeniasTerminatedNCT00472433Phase 2
- Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete RemissionCompletedNCT00458523Phase 2
- Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1HCompletedNCT00458250Phase 1
- Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell LymphomasCompletedNCT00453427Phase 1/2
- The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCLTerminatedNCT00441025Phase 2
- Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantCompletedNCT00410657Phase 2
- Stem Cell Transplant in Sickle Cell Disease and ThalassemiaActive, not recruitingNCT00408447Phase 2
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's LymphomaStatus unknownNCT00363090Phase 1/2
- Allogeneic Stem Cell Transplantation in Chronic Lymphocytic LeukemiaStatus unknownNCT00337519Phase 2
- Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic LeukemiaStatus unknownNCT00336206Not applicable
- Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLLCompletedNCT00330252Phase 1
- Simultaneous Pancreas-kidney Transplantation With Campath ProtocolCompletedNCT00316810Phase 3
- Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney TransplantationCompletedNCT00309270Phase 2
- A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 DeletionCompletedNCT00292760Phase 2
- Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaCompletedNCT00278213Phase 2
- Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic LeukemiaCompletedNCT00276809Phase 2
- Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous FludarabineCompletedNCT00274976Phase 2
- To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity ConditioningWithdrawnNCT00226512Phase 3
- A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal TransplantationCompletedNCT00214266Phase 2
- A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes MellitusWithdrawnNCT00214214Phase 1
- Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney TransplantationTerminatedNCT00177138Phase 4
- Alemtuzumab Induction in Islet TransplantationCompletedNCT00175253Phase 2
- A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver TransplantationCompletedNCT00166556Phase 2
- Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00162851Phase 2
- Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary SyndromeStatus unknownNCT00157274Phase 2
- Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency SyndromeCompletedNCT00152100Phase 1
- Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft RejectionCompletedNCT00147381Phase 3
- Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00143065Phase 2
- Phase II Study of Campath-1H Antibody to Treat Waldenstrom's MacroglobulinemiaCompletedNCT00142181Phase 2
- Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's DiseaseWithdrawnNCT00129753Phase 2
- Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic MalignanciesTerminatedNCT00113048Phase 1
- Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
- Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00104975Phase 1